Spark Therapeutics Inc. said it would charge $850,000 a patient for a pioneering new treatment for a hereditary form of vision loss—below the $1 million price tag the company had considered, but still a milestone for ever-rising drug prices in the U.S.
from WSJ.com: US Business http://ift.tt/2qgvDfg
via IFTTT
No comments:
Post a Comment